In human HNSCC, Smad4 expression was reduced in 86% of tumors and 67% of surrounding nonmalignant mucosa, while a Smad4‐deficient mouse model demonstrated enhanced HNSCC susceptibility.10, 82. This evidence concerns the gene SMAD4 and head and neck squamous cell carcinoma.